These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36064440)

  • 21. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Harmonizing development, approval and access of drugs for rare diseases in Europe.].
    Costa E; Magrini N
    Recenti Prog Med; 2022; 113(7):407-410. PubMed ID: 35852074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries.
    Lichtenberg FR
    Econ Hum Biol; 2022 Aug; 46():101124. PubMed ID: 35344806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bridging the Gap between Health and Social Care for Rare Diseases: Key Issues and Innovative Solutions.
    Castro R; Senecat J; de Chalendar M; Vajda I; Dan D; Boncz B;
    Adv Exp Med Biol; 2017; 1031():605-627. PubMed ID: 29214594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil.
    Kameda K
    Dev World Bioeth; 2014 Aug; 14(2):101-8. PubMed ID: 24761744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need.
    Dionne PA; Ali F; Grobler M
    J Health Econ Outcomes Res; 2015; 3(1):13-23. PubMed ID: 34430665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conflicts of interest in research involving human beings.
    Greco D; Diniz NM
    J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing 15 proposals for promoting innovation and access to medicines globally.
    Hoffman SJ; So K;
    Ann Glob Health; 2014; 80(6):432-43. PubMed ID: 25960092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incentives and disincentives to drug innovation: evidence from recent literature.
    Lee Mendoza R
    J Med Econ; 2019 Aug; 22(8):713-721. PubMed ID: 31038374
    [No Abstract]   [Full Text] [Related]  

  • 30. Consensus document on European brain research.
    Olesen J; Baker MG; Freund T; di Luca M; Mendlewicz J; Ragan I; Westphal M
    J Neurol Neurosurg Psychiatry; 2006 Aug; 77 Suppl 1(Suppl 1):i1-49. PubMed ID: 16845120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
    Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
    Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of patient organisations in research and development: Evidence from rare diseases.
    Gentilini A; Miraldo M
    Soc Sci Med; 2023 Dec; 338():116332. PubMed ID: 37866173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Why are new drugs so expensive?].
    Le Galès C
    Med Sci (Paris); 2018 Apr; 34(4):354-361. PubMed ID: 29658480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asian innovation in pharmaceutical and medical device industry - beyond tomorrow.
    Jakovljevic M; Wu W; Merrick J; Cerda A; Varjacic M; Sugahara T
    J Med Econ; 2021 Nov; 24(sup1):42-50. PubMed ID: 34915798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model.
    Riccaboni M; Swoboda T; Van Dyck W
    Health Policy; 2022 Jun; 126(6):534-540. PubMed ID: 35459584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SHAFE Mapping on Social Innovation Ecosystems.
    Dantas C; Louceiro J; Vieira J; van Staalduinen W; Zanutto O; Mackiewicz K
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Australia in 2030: what is our path to health for all?
    Backholer K; Baum F; Finlay SM; Friel S; Giles-Corti B; Jones A; Patrick R; Shill J; Townsend B; Armstrong F; Baker P; Bowen K; Browne J; Büsst C; Butt A; Canuto K; Canuto K; Capon A; Corben K; Daube M; Goldfeld S; Grenfell R; Gunn L; Harris P; Horton K; Keane L; Lacy-Nichols J; Lo SN; Lovett RW; Lowe M; Martin JE; Neal N; Peeters A; Pettman T; Thoms A; Thow AMT; Timperio A; Williams C; Wright A; Zapata-Diomedi B; Demaio S
    Med J Aust; 2021 May; 214 Suppl 8():S5-S40. PubMed ID: 33934362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Access to medicines for rare diseases: regulatory aspects and public health priorities.].
    Costa E; Grimaldi G; Del Grosso V; Isgrò A; Genazzani A
    Recenti Prog Med; 2022; 113(7):415-424. PubMed ID: 35852076
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.